The Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
A Prospective Observational Study on the Level of Patient Participation in Lung and Esophageal Cancer Patients Treated With Definitive Radiochemotherapy.
1 other identifier
observational
500
1 country
1
Brief Summary
This study aims to assess the level of participation of thoracic cancer patients undergoing definitive radiotherapy and chemotherapy ± immunotherapy in their medical processes and the association between the level of participation and patients' side effects, quality of life, and long-term survival. Additionally, this study will rate the level of participation from both the patients' and medical staff's perspectives and will compare the differences in ratings from these two viewpoints, as well as their impact on treatment outcomes.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2022
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2022
CompletedFirst Submitted
Initial submission to the registry
August 25, 2023
CompletedFirst Posted
Study publicly available on registry
August 31, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
May 30, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
May 30, 2027
December 10, 2024
December 1, 2024
5 years
August 25, 2023
December 5, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Incidence of >=Grade 3 toxicities
The percentage of patients who develop \>=Grade 3 toxicities
2 years
Secondary Outcomes (2)
Overall survival
2 years
Progression-free survival
2 years
Study Arms (1)
Observational group
Patients undergoing definitive radiochemotherapy ± immunotherapy will be assessed about the level of participation in their medical processes.
Eligibility Criteria
Patients with locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, or esophageal cancer
You may qualify if:
- Locally advanced non-small cell lung cancer, limited-stage small cell lung cancer, and esophageal cancer.
- Planned to undergo definitive chemoradiotherapy ± immunotherapy;
- Males or females aged 18 to 75;
- Able to communicate with medical staff.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Sun Yat-sen University
Guangzhou, 510060, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
August 25, 2023
First Posted
August 31, 2023
Study Start
June 1, 2022
Primary Completion (Estimated)
May 30, 2027
Study Completion (Estimated)
May 30, 2027
Last Updated
December 10, 2024
Record last verified: 2024-12